Stock VOR VOR BIOPHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Vor Biopharma Inc.

Equities

VOR

US9290331084

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.69 USD -0.59% Intraday chart for Vor Biopharma Inc. -1.17% -24.89%
Mar. 21 Stifel Cuts Price Target on Vor Biopharma to $12 From $15, Maintains Buy Rating MT
Mar. 21 Oppenheimer Cuts Vor Biopharma Price Target to $15 From $18, Maintains Outperform Rating MT

Business Summary

Vor Biopharma Inc. is a clinical-stage cell and genome engineering therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solutions for patients suffering from hematological malignancies. Its proprietary platform leverages expertise in hematopoietic stem cell (HSC) biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. The Company’s lead engineered hematopoietic stem cells (eHSC) product candidate include tremtelectogene empogeditemcel (trem-cel), for the treatment for acute myeloid leukemia (AML) and other blood cancers. It is designed to replace the standard of care in transplant settings for patients suffering from acute myeloid leukemia (AML) and other blood cancers. Its VBP101 is a Phase I/II a multicenter, open-label, first-in-human study of trem-cel in patients with AML.

Number of employees: 168

Managers

Managers TitleAgeSince
Bob Ang CEO
 Chief Executive Officer 49 19-08-06
Nathan Jorgensen DFI
 Director of Finance/CFO 47 20-04-30
Tirtha Chakraborty CTO
 Chief Tech/Sci/R&D Officer 51 19-09-30
Eyal Attar CTO
 Chief Tech/Sci/R&D Officer 53 22-10-11
Sarah Spencer IRC
 Investor Relations Contact - -
Tania Philipp HRO
 Human Resources Officer 52 19-11-30
John C. King PRN
 Corporate Officer/Principal 49 20-07-31
Robert G. Pietrusko LAW
 General Counsel 76 20-03-31

Members of the board

Members of the board TitleAgeSince
David Lubner BRD
 Director/Board Member 60 20-07-29
Matt Patterson CHM
 Chairman 52 20-10-19
Bob Ang CEO
 Chief Executive Officer 49 19-08-06
Bill Lundberg BRD
 Director/Board Member 60 19-07-30
Daniella Beckman BRD
 Director/Board Member 45 20-07-15
Joshua Resnick BRD
 Director/Board Member 49 19-01-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 68,226,070 67,426,408 ( 98.83 %) 10,299 ( 0.0151 %) 98.83 %

Shareholders

NameEquities%Valuation
RA Capital Management LP
33.37 %
22,748,880 33.37 % 54 M $
Fidelity Management & Research Co. LLC
11.18 %
7,618,948 11.18 % 18 M $
Paradigm BioCapital Advisors LP
9.473 %
6,457,293 9.473 % 15 M $
5AM Venture Management LLC
9.332 %
6,361,723 9.332 % 15 M $
Laurion Capital Management LP
4.669 %
3,182,889 4.669 % 8 M $
Artal Group SA
3.444 %
2,347,424 3.444 % 6 M $
BlackRock Advisors LLC
3.144 %
2,143,566 3.144 % 5 M $
Vanguard Fiduciary Trust Co.
2.558 %
1,743,463 2.558 % 4 M $
Woodline Partners LP
1.630 %
1,111,123 1.630 % 3 M $
Johnson & Johnson Innovation - JJDC, Inc.
1.576 %
1,074,658 1.576 % 3 M $

Company contact information

Vor Biopharma, Inc.

100 Cambridgepark Drive Suite 101

02140, Cambridge

+

http://www.vorbiopharma.com
address Vor Biopharma Inc.(VOR)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.69 USD
Average target price
14.69 USD
Spread / Average Target
+769.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VOR BIOPHARMA INC. Stock Vor Biopharma Inc.
-24.89% 115M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VOR Stock
  4. Company Vor Biopharma Inc.